Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc., despite the request metadata) on September 17, 2025. The filing reports the entry into a Fifth Amendment to a previously disclosed Agreement and Plan of Merger with Decoy Therapeutics Inc. and its subsidiaries.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on the modification of capital structure terms related to a pending merger.
Material Changes
The primary material change is the amendment of the conversion and redemption terms for Salarius Pharmaceuticals' Series A and Series B Non-Voting Convertible Preferred Stock:
- Baseline Conversion Price: Established a new "Initial Issuance Price" of $10.50 per share as the baseline for calculating proportional adjustments to the conversion ratio in the event of a dilutive subsequent financing.
- Price Protection Floor: Set a floor price of $3.75 per share as the lowest per share price used in price protection calculations triggered by a subsequent financing.
- Redemption Price Adjustment: Modified the Series B Preferred Stock redemption price to equal the Initial Issuance Price ($10.50) multiplied by 1,000.
Guidance, Outlook, and Risks
The filing states that, except for the modifications described above, the terms of the Merger Agreement remain in full force and effect. No specific financial guidance, management outlook, or new risk factors are disclosed in this text. The filing notes that the descriptions of the amendment are qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the full text of the Fifth Amendment to the Agreement and Plan of Merger (Exhibit 2.1) to understand the complete scope of the changes.
- Review the Certificates of Designation for Series A (Exhibit 2.2) and Series B (Exhibit 2.3) Preferred Stock to confirm the exact mechanics of the new conversion and redemption formulas.
- Confirm the status of the "Qualified Financing" and whether any "Subsequent Financing" has occurred that would trigger the new price protection mechanisms.
- Note the discrepancy between the request metadata (Decoy Therapeutics) and the actual registrant (Salarius Pharmaceuticals).